

MOREPEN

Date: 04/08/2026

To,

National Stock Exchange of India Ltd.	**BSE Limited**
Exchange Plaza, Bandra Kurla Complex,	Phiroze Jeejeebhoy Towers,
Bandra (East), Mumbai- 400 051	Dalal Street, Mumbai- 400 001
Symbol: MOREPENLAB	**Scrip Code: 500288**

Subject: Outcome of the meeting of the Board of Directors of the company

Dear Sir/ Madam,

This is to inform you that the Board of Directors of the company, in their meeting held today i.e., Tuesday, 4th August 2026 *(commenced at 11.30 a.m. and concluded at 1.20 p.m.)*, have, considered and approved, *inter-alia:*

1. Un-audited standalone & consolidated financial results of the company for the quarter ended 30th June 2026, based on the recommendation of Audit Committee, in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

   The financial results along with the limited review reports of the auditors of the company, are enclosed herewith as **Annexure-A.**

2. Record date as Saturday, 19th September 2026, for the purpose of determining the members eligible to receive final dividend for the financial year ended 31st Match 2026, if approved by members at their 41st Annual General Meeting ('AGM'), in accordance with Regulation 42 of Listing Regulations.

3. Subject to the approval of members of the company at the forthcoming 41st AGM, extension of approved timeline for hiving off Medical Devices Business, a material related party transaction, into Morepen Medipath Limited *(formerly, Morepen Medtech Limited)*, a subsidiary company, as a going concern on slump sale basis.

4. Subject to the approval of members at the 41st AGM of the company, re-appointment of Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director of the company, pursuant to the recommendation of the Nomination and Remuneration Committee, for a further period of three (3) years effective from 20th October 2026 to 19th October 2029 *(both days inclusive)*.

   The details as required under the SEBI Listing Regulations read with SEBI master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, is given in the **Annexure-B.**

Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



5. The notice of the 41st AGM of members of the company, scheduled to be held on Saturday, 26th September 2026 through video conferencing / other audio-visual means, in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava

Digitally signed by Vipul Kumar Srivastava
DN: c=IN, o=Personal, title=5965, pseudonym=27r5blzck0qifj1phgwaves8do39myx6, 2.5.4.20=824342118b98561bde2c7d0b1ad7b62196947c41b456377b3cbe9a983c527111, postalCode=110078, st=Delhi, serialNumber=1363f5e45381fa8dd66dee65e3bc15c08e5b41badb071c1b5de04ef8874db223, cn=Vipul Kumar Srivastava
Date: 2026.08.04 13:40:29 +05'30'

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID : spbabuta@hotmail.com, Website : www.babuta.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF MOREPEN LABORATORIES LIMITED

1. We have reviewed the accompanying statement of consolidated financial results of Morepen Laboratories Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the ("Group") for the quarter **ended June 30, 2026** (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following Group entities:

   Parent:
   Morepen Laboratories Limited

   Indian Subsidiary:
   a) Morepen Devices Limited

S.P. BABUTA & ASSOCIATES CHARTERED ACCOUNTANTS 86348 CHANDIGARH

b) Morepen Rx Ltd.
c) Morepen Medipath Limited (*formerly known as* Morepen Medtech Limited)
d) Sigmacheck Health Private Limited

Foreign Subsidiary:
a) Morepen Bio Inc., USA
b) Morepen Labs FZE., UAE (*formerly known as* Morepen Labs FZCO)
c) Morepen Medical Equipment Trading L.L.C., UAE

5. Based on our review conducted and procedures performed as stated in paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of five subsidiaries i.e. Morepen Devices Limited, Morepen Rx Ltd., Morepen Bio Inc., Morepen Medical Equipment Trading L.L.C and Morepen Labs FZE, included in the statement, whose interim financial results reflect total profit/(loss) after tax (before consolidation adjustments) of Rs.238.71 Lakhs (comprising of total revenue of Rs.8045.37 Lakhs and total expenses of Rs.7803.83 Lakhs) and total comprehensive income (before consolidation adjustments) of Rs.238.71 Lakhs for the quarter ended June 30, 2026.

   The interim financial results of the Indian subsidiaries have been reviewed by their auditors whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   The subsidiaries, Morepen Bio Inc., Morepen Medical Equipment Trading L.L.C and Morepen Labs FZE are located outside India. The interim financial results of all of these subsidiaries have been prepared in accordance with accounting principles generally accepted in their respective countries and have been reviewed by their auditors under generally accepted auditing standards applicable in that country. The Company's management has compiled the interim financial information/financial results of Morepen Bio Inc, Morepen Medical Equipment Trading L.L.C and Morepen Labs FZE from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management.

   Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of Morepen Bio Inc., Morepen Medical Equipment Trading L.L.C. and Morepen Labs FZE is

S.P. BABUTA & ASSOCIATES CHARTERED ACCOUNTANTS based solely on the report of their respective auditors, the conversion adjustments prepared by the Management of the Company, and reviewed by us, and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For S.P. Babuta & Associates
Chartered Accountants
F. No: 007657N

S.P. BABUTA & ASSOCIATES
CHARTERED ACCOUNTANTS
86348
CHANDIGARH

CA S. P. Babuta
Managing Partner
FCA, IP, DISA, CCA
GST Cert, Forensic Auditor
Membership No.: 086348

Dated: 04/08/2026
Place: Gurugram, Haryana

UDIN No.: 26086348PZTEHD9323

Morepen Laboratories Limited
CIN- L24231HP1984PLC006028
Statement of Unaudited Financial Results - Consolidated
For the Quarter Ended 30th June, 2026

(Rs.in Lakhs, except per share data)

Sl.	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	**Income**				
	Revenue from operations (Net)	57012.81	48471.59	42523.88	180569.15
	Other Income	518.34	846.37	440.85	2131.41
	Total Income	**57531.15**	**49317.96**	**42964.73**	**182700.56**
2.	**Expenditure**				
	a) Cost of Materials Consumed	32838.05	29057.54	23770.89	104310.57
	b) Purchases of stock - in - trade	964.09	1767.05	1703.99	8246.05
	c) Changes in inventories of Finished goods, Work -in-progress and Stock-in-trade	(1931.79)	(871.93)	761.59	(214.97)
	d) Employee Benefits Expense	6244.35	5875.57	5523.67	23273.94
	e) Finance Costs	484.13	387.66	403.78	1641.37
	f) Depreciation and Amortization Expense	834.88	574.70	902.51	3643.47
	g) Power and Fuel	1280.67	1218.99	1055.80	4489.72
	h) Travelling Expenses	564.66	623.73	618.91	2332.75
	i) Selling and Distribution Expenses	5331.43	3490.81	3039.64	9897.60
	j) Other Expenses	3467.94	4865.09	3632.31	15670.60
	Total Expenditure	**50078.41**	**46989.21**	**41413.09**	**173291.10**
3.	**Profit before exceptional items and tax (1-2)**	**7452.74**	**2328.75**	**1551.64**	**9409.46**
4.	Exceptional items - Income	-	-	-	2582.54
5.	**Profit before Tax (3+4)**	**7452.74**	**2328.75**	**1551.64**	**11992.00**
6.	**Tax Expense**				
	Current Tax	1818.85	(88.97)	378.12	1592.87
	Earlier Periods Tax	-	-	32.86	(13.15)
	Deferred Tax	(0.69)	847.63	-	847.63
	Total Tax	**1818.16**	**758.66**	**410.98**	**2427.35**
7.	**Net Profit for the period (5-6)**	**5634.58**	**1570.09**	**1140.66**	**9564.65**
8.	Share of Minority Interest in Profit/(Loss)	(5.36)	(4.37)	65.83	76.97
9.	**Net Profit after Minority Interest (7-8)**	**5639.94**	**1574.46**	**1074.83**	**9487.68**
10.	**Other Comprehensive Income/ (Loss) (OCI)**				
	(i) Items that will not be reclassified to Profit & Loss				
	Fair value changes on Equity Instruments through OCI	-	709.83	-	709.83
	Re-measurement gain/(loss) on Defined Benefit Plans	23.23	4.95	79.05	9.69
	Income tax relating to items that will not be reclassified	(4.22)	(99.66)	(20.05)	(100.59)
		19.01	**615.12**	**59.00**	**618.93**
	(ii) Items that will be reclassified to Profit & Loss	-	21.19	-	(0.02)
	Other Comprehensive Income/ (Loss) (Net of Tax)	**19.01**	**636.31**	**59.00**	**618.91**
11.	**Total Comprehensive Income (9+10)**	**5658.95**	**2210.77**	**1133.83**	**10106.59**
12.	**Paid-up Equity Share Capital of Face Value of Rs.2/- each**	**10958.41**	**10958.41**	**10958.41**	**10958.41**
13.	**Other Equity**				**113685.46**
14.	**Earning Per Share (in Rs.)**				
	- Basic & Diluted EPS	1.03	0.28	0.20	1.73

Notes :

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 4, 2026. A Limited review of the same has been carried out by the Statutory Auditors.
2. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31, 2025.
3. The Company is engaged in the Pharmaceutical Business Segment.

S.P. BABUTA & ASSOCIATES CHARTERED ACCOUNTANTS CHANDIGARH

For and on behalf of the Board of Directors

Place : Gurugram, Haryana
Date : August 4, 2026

(Sushil Suri)
Chairman & Managing Director

Annexure - 1				
List of entities included in the Consolidated Financial Results :				
Sl.	**Name of the Entity**	**Status**	**% holding**	**Held by Morepen Laboratories Ltd. through**
1	Morepen Laboratories Ltd.	Holding Company	Parent Co.	Parent Company
2	Morepen Rx Ltd.	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
3	Morepen Devices Ltd.	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
4	Morepen Bio Inc., USA	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
5	Morepen Labs -FZE, Dubai (Formely Morepen Labs- FZCO, Dubai)	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
6	Morepen Medipath Limited (Formerly Morepen Medtech Limited)	Subsidiary	51%	Morepen Laboratories Ltd.
7	Morepen Medical Equipment Trading L.L.C, Dubai	Subsidiary	51%	Morepen Medipath Ltd.
8	Sigmacheck Health Private Limited	Subsidiary	51%	Morepen Medipath Ltd.

S.P. BABUTA & ASSOCIATES CHARTERED ACCOUNTANTS CHANDIGARH

S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID: spbabuta@hotmail.com, Website: www.babuta.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF MOREPEN LABORATORIES LIMITED

1. We have reviewed the accompanying statement of standalone financial results of Morepen Laboratories Limited (the "Company") for the quarter **ended June 30, 2026** (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.P. Babuta & Associates
Chartered Accountants
F. No: 007657N

S.P. BABUTA & ASSOCIATES
CHARTERED ACCOUNTANTS

CA S.P. Babuta
Managing Partner
FCA, IP, DISA, CCA
GST Cert, Forensic Auditor
Membership No.: 086348

Dated: 04/08/2026
Place: Gurugram, Haryana

UDIN No.: 26086348PJOUGF6981

Morepen Laboratories Limited
CIN- L24231HP1984PLC006028
Statement of Unaudited Financial Results - Standalone
For the Quarter Ended 30th June, 2026

(Rs.in Lakhs, except per share data)

Sl.	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	**Income**				
	Revenue from operations (Net)	54104.13	46281.28	39128.43	168119.50
	Other Income	531.09	881.72	409.23	2149.51
	Total Income	**54635.22**	**47163.00**	**39537.66**	**170269.01**
2.	**Expenditure**				
	a) Cost of Materials Consumed	32838.05	29057.54	23770.89	104310.57
	b) Purchases of stock - in - trade	434.72	499.98	130.73	1502.34
	c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	(2030.49)	(551.86)	982.96	323.19
	d) Employee Benefits Expense	5578.27	5437.37	4668.84	20627.70
	e) Finance Costs	477.85	387.23	381.16	1609.71
	f) Depreciation and Amortization Expense	797.94	63.23	787.92	2930.81
	g) Power and Fuel	1280.67	1219.06	1055.75	4489.72
	h) Travelling Expenses	432.16	591.54	426.17	1849.18
	i) Selling and Distribution Expenses	4307.20	3285.06	2626.56	9041.26
	j) Other Expenses	3303.69	4411.26	3571.40	14767.70
	Total Expenditure	**47420.06**	**44400.41**	**38402.38**	**161452.18**
3.	**Profit before exceptional items and tax (1-2)**	**7215.16**	**2762.59**	**1135.28**	**8816.83**
4.	Exceptional items - Income	-	-	-	109.59
5.	**Profit before Tax (3+4)**	**7215.16**	**2762.59**	**1135.28**	**8926.42**
6.	**Tax Expense**				
	Current Tax	1815.33	(98.93)	296.30	1484.62
	Earlier Periods Tax	-	-	32.86	(13.15)
	Deferred Tax	-	849.20	-	849.20
	Total Tax	**1815.33**	**750.27**	**329.16**	**2320.67**
7.	**Net Profit for the period (5-6)**	**5399.83**	**2012.32**	**806.12**	**6605.75**
8.	**Other Comprehensive Income (OCI)**				
	Items that will not be reclassified to Profit & Loss -				
	Fair value changes on Equity Instruments through OCI	-	709.83	-	709.83
	Re-measurement gain/(loss) on Defined Benefit Plans	23.23	(4.20)	76.82	(3.57)
	Income Tax relating to the items that will not be reclassified	(4.22)	(100.70)	(20.05)	(100.59)
	Other Comprehensive Income (Net of Tax)	**19.01**	**604.93**	**56.77**	**605.67**
	Total Comprehensive Income (7+8)	**5418.84**	**2617.25**	**862.89**	**7211.42**
9.	**Paid-up Equity Share Capital of Face Value of Rs.2/- each**	**10958.41**	**10958.41**	**10958.41**	**10958.41**
10.	**Other Equity**				**113317.44**
11.	**Earning Per Share (in Rs.)**				
	- Basic & Diluted EPS	0.99	0.37	0.15	1.21

Notes :

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 4, 2026. A Limited review of the same has been carried out by the Statutory Auditors.
2. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31, 2025.
3. The Company is engaged in the Pharmaceutical Business Segment.

S.P. BABUTA & ASSOCIATES CHARTERED ACCOUNTANTS CHANDIGARH

For and on behalf of the Board of Directors

MOREPEN LABORATORIES LIMITED Gurugram (Haryana)

Place : Gurugram, Haryana
Date : August 4, 2026

(Sushil Suri)
Chairman & Managing Director



MOREPEN

40 Years of Excellence

Annexure - B

Disclosure in terms of Regulation 30 read with SEBI master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026

S. No.	Particulars	Details
1.	Reason for change *viz.* appointment, resignation, removal, death or otherwise;	Re-appointment of Mr. Sushil Suri (DIN: 00012028) as the Chairman & Managing Director on account of the completion of tenure of three (3) years on 19th October 2026.
2.	Date of appointment/ reappointment/ cessation (as applicable) and terms of appointment /reappointment;	**Date of re-appointment**: 20th October 2026 **Term of re-appointment:** Based on the recommendation of the Nomination and Remuneration Committee, the Board, has approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a further period of three (3) years effective from 20th October 2026 to 19th October 2029 *(both days inclusive)*, subject to the approval of members at the 41st AGM of the company.
3.	Brief Profile (in case of appointment)	Mr. Sushil Suri has more than 30 years of experience in pharmaceuticals industry and has played an active role in the evolution of the pharma sector since 1992. His experience and expertise span all segments of the pharma industry including the fields of strategic & financial planning, manufacturing, capital structuring, collaborations and joint ventures etc. He is a qualified Chartered Accountant & a Fellow member of the Institute of Chartered Accountants of India.
4.	Disclosure of relationship between directors (in case of appointment of a director).	Mr. Sushil Suri, Chairman & Managing Director and promoter of the Company, is the brother of Mr. Sanjay Suri, Managing Director, a member of promoter group of the company.
5.	Other information	Mr. Sushil Suri is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority.

Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com